Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Mantle-Cell × Axitinib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 64 Kidney Neoplasms 17 Neoplasms 16 Carcinoma, Non-Small-Cell Lung 10 Neoplasm Metastasis 9 Colorectal Neoplasms 8 Carcinoma, Hepatocellular 8 Melanoma 7 Carcinoma 7 Glioblastoma 5 Lung Neoplasms 4 Clear-cell metastatic renal cell carcinoma 4 Uterine Cervical Neoplasms 3 Recurrence 3 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Thyroid Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2 Skin Neoplasms 2 Sarcoma 2 Pheochromocytoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Paraganglioma 2 Liver Neoplasms 2 Kidney Diseases 2 Carcinoma, Adenoid Cystic 2 Breast Neoplasms 2 Advanced Solid Tumors 2

Interventions

Rituximab 225 Cyclophosphamide 201 fludarabine phosphate 108 Peripheral Blood Stem Cell Transplantation 103 Filgrastim 87 Etoposide 76 Cytarabine 70 ibrutinib 68 Mycophenolic Acid 67 Bortezomib 66 Whole-Body Irradiation 63 Cyclosporine 63 Melphalan 59 Lenalidomide 59 Bendamustine Hydrochloride 58 Vincristine 53 Radiotherapy 53 fludarabine 51 Tacrolimus 50 Doxorubicin 48 Busulfan 48 Methotrexate 47 Antilymphocyte Serum 42 Prednisone 41 Carmustine 40 Dexamethasone 38 Granulocyte Colony-Stimulating Factor 33 venetoclax 31 acalabrutinib 31 zanubrutinib 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00700258 2024-09-23

STAR-TOR

Pfizer

1,520 enrolled 24 charts

Carcinoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡